NLS Pharmaceutics (NASDAQ:NLSP) AG CEO Alex Zwyer joined Proactive to discuss the Stans, Switzerland-based clinical-stage biopharmaceutical company's most recent developments on its potential treatment for chronic sleep disorder, narcolepsy.
Zwyer says US-based recruitment and enrollment is going 'very well' of its Phase 2a clinical trial using its lead product candidate Quilience to treat patients, with interim top-line results to be reported in 1Q in 2022.